Cargando…

Cost effectiveness of palivizumab in Spain: an analysis using observational data

OBJECTIVES: To assess the cost effectiveness of palivizumab for prevention of severe respiratory syncytial virus (RSV) disease in high-risk infants in Spain, incorporating country-specific observational hospitalisation data. METHODS: An existing decision tree model, designed using data from a large...

Descripción completa

Detalles Bibliográficos
Autores principales:	Nuijten, Mark J., Wittenberg, Wolfgang
Formato:	Texto
Lenguaje:	English
Publicado:	Springer-Verlag 2009
Materias:	Original Paper
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2816247/ https://www.ncbi.nlm.nih.gov/pubmed/19967425 http://dx.doi.org/10.1007/s10198-009-0206-x

Ejemplares similares

The Medicaid Cost of Palivizumab
por: Ambrose, Christopher S., et al.
Publicado: (2015)

Cost-utility analysis of Palivizumab for Respiratory Syncytial Virus infection prophylaxis in preterm infants: update based on the clinical evidence in Spain
por: Sanchez-Luna, M., et al.
Publicado: (2017)

Assessing Variation in the Cost of Palivizumab for Respiratory Syncytial Virus Prevention in Preterm Infants
por: Shahabi, Ahva, et al.
Publicado: (2017)

Should we use Palivizumab immunoprophylaxis for infants against respiratory syncytial virus? – a cost-utility analysis
por: Ginsberg, Gary M., et al.
Publicado: (2018)

Is immunization with palivizumab really effective in high-risk children?
por: Raguž, Marjana Jerković, et al.
Publicado: (2023)

Effectiveness of palivizumab in preventing respiratory syncytial virus infection in high-risk children
por: Viguria, Natividad, et al.
Publicado: (2021)

Palivizumab Compliance by Infants in Puerto Rico During the 2009–2010 Respiratory Syncytial Virus Season
por: Matías, Israel, et al.
Publicado: (2014)

Effectiveness of Palivizumab in High-risk Infants and Children: A Propensity Score Weighted Regression Analysis
por: Anderson, Evan J., et al.
Publicado: (2017)

Impact of the use of immunoglobulin palivizumab in the State of São Paulo: a cohort study
por: Gonçalves, Ivana Regina, et al.
Publicado: (2017)

A post-incorporation study on the use of palivizumab in the Brazilian public health system
por: Batista, Joanna d’Arc Lyra, et al.
Publicado: (2021)

Cost–effectiveness analysis of quadrivalent influenza vaccine in Spain
por: García, Amos, et al.
Publicado: (2016)

Respiratory infections in children up to two years of age on prophylaxis with palivizumab
por: Monteiro, Ana Isabel M. P., et al.
Publicado: (2014)

Effect of delayed palivizumab administration on respiratory syncytial virus infection-related hospitalisation: A retrospective, observational study
por: Kamori, Akiko, et al.
Publicado: (2021)

Respiratory Syncytial Virus Immunoprophylaxis with Palivizumab: 12-Year Observational Study of Usage and Outcomes in Canada
por: Mitchell, Ian, et al.
Publicado: (2021)

Effectiveness of palivizumab immunoprophylaxis in preterm infants against respiratory syncytial virus disease in Qatar
por: Abushahin, Ahmad, et al.
Publicado: (2018)

Safety and pharmacokinetics of extended use of palivizumab in Saudi Arabian infants and children
por: al-Alaiyan, Saleh, et al.
Publicado: (2015)

Palivizumab in the prevention of severe respiratory syncytial virus infection in children with congenital heart disease; a novel cost-utility modeling study reflecting evidence-based clinical pathways in Spain
por: Schmidt, Ralph, et al.
Publicado: (2017)

Practical issues in handling data input and uncertainty in a budget impact analysis
por: Nuijten, M. J. C., et al.
Publicado: (2010)

Development of a palivizumab specialty pharmacy management program
por: Harlan, Lana, et al.
Publicado: (2019)

Studies Recommending Palivizumab Restriction Have Serious Deficiencies
por: Stewart, Dan L.
Publicado: (2010)

Cost-minimization analysis of immunoglobulin treatment of primary immunodeficiency diseases in Spain
por: Alsina, Laia, et al.
Publicado: (2021)

Serum palivizumab level is associated with decreased severity of respiratory syncytial virus disease in high-risk infants
por: Forbes, Michael L, et al.
Publicado: (2014)

Use of palivizumab is underestimated in the Swedish Prescribed Drug Register – implications for register-based drug studies
por: Linder, Marie, et al.
Publicado: (2014)

Palivizumab’s real-world effectiveness: a population-based study in Ontario, Canada, 1993–2017
por: Fitzpatrick, Tiffany, et al.
Publicado: (2021)

Pulmonary Deposition of Radionucleotide-Labeled Palivizumab: Proof-of-Concept Study
por: Rajapaksa, Anushi E., et al.
Publicado: (2020)

Impact of Palivizumab on RSV Hospitalizations for Children with Hemodynamically Significant Congenital Heart Disease
por: Chang, Ruey-Kang R., et al.
Publicado: (2009)

Post-translational modifications and glycoprofiling of palivizumab by UHPLC–RPLC/HILIC and mass spectrometry
por: Sran, Kulwinder Singh, et al.
Publicado: (2022)

Risk factors for recurrent wheezing in preterm infants who received prophylaxis with palivizumab
por: Manini, Mariana Bueno, et al.
Publicado: (2021)

Social economic costs of COPD in Extremadura (Spain): an observational study
por: Merino, María, et al.
Publicado: (2018)

Neonatal outcomes following new reimbursement limitations on palivizumab in Italy
por: Belleudi, Valeria, et al.
Publicado: (2018)

Reappraisal of the Subtropical Guidelines on Palivizumab Prophylaxis in Congenital Heart Disease
por: Chiu, Shuenn-Nan, et al.
Publicado: (2022)

Respiratory syncytial virus and palivizumab prophylaxis in the COVID-19 era
por: Taylor, Richard S.
Publicado: (2021)

A Systematic Review of Compliance with Palivizumab Administration for RSV Immunoprophylaxis
por: Frogel, Michael
Publicado: (2010)

Cost-Utility Analysis: Current Methodological Issues and Future Perspectives
por: Nuijten, Mark J. C., et al.
Publicado: (2011)

Cost comparison of second-line treatment options for late stage non-small-cell lung cancer: cost analysis for Italy
por: Schwander, Bjoern, et al.
Publicado: (2012)

Palivizumab reimbursement criteria and neonatal RSV hospitalisation: a regional retrospective review
por: Belleudi, Valeria, et al.
Publicado: (2021)

The Danish National Prescription Registry in studies of a biological pharmaceutical: palivizumab – validation against two external data sources
por: Haerskjold, Ann, et al.
Publicado: (2015)

Compliance with The RSV Immunoprophylaxis Dosing Schedule in The Polish Registry for Palivizumab (2008-2014)
por: Borecka, Róża, et al.
Publicado: (2019)

Cost-effectiveness of antibiotics for COPD management: observational analysis using CPRD data
por: Ronaldson, Sarah J., et al.
Publicado: (2017)

Palivizumab Prophylaxis for Respiratory Syncytial Virus: Examining the Evidence Around Value
por: Olchanski, Natalia, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_1bsf381of649omek5ovkokio6f